PBM Act
Summary
The PBM Act (S. 4509) prohibits common ownership of pharmacy benefit managers and pharmacies, directly targeting CVS Health, UnitedHealth Group, and Cigna. At an early legislative stage, near-term probability is low, but if enacted, would force major divestitures and reshape the healthcare supply chain.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The PBM Act targets vertical integration of PBMs and pharmacies, with CVS and UnitedHealth most at risk.
- 2.No funding is involved; it is a structural prohibition requiring divestiture.
- 3.Early stage legislation with low near-term probability but significant long-term implications for the healthcare sector.
Market Implications
The PBM Act introduces a clear bearish catalyst for CVS and UnitedHealth, as their vertical integration is directly challenged. Without real market data, the focus should be on the legislative process: if the bill gains cosponsors or advances to markup, expect headline risk and potential valuation compression. For Cigna, the impact is smaller but still notable. In contrast, independent pharmacy chains like Walgreens ($WBA) may see relative outperformance if the bill reduces PBM steering to captive pharmacies, though this is peripheral.
Full Analysis
On May 13, 2026, Sen. Warren introduced the Patients Before Monopolies Act (PBM Act, S. 4509) to separate pharmacy benefit managers (PBMs) from pharmacies under common ownership. The bill was read twice and referred to the Senate Judiciary Committee. The legislation is in an early stage with no committee action yet. It does not authorize any spending—it is a structural prohibition, not a funding bill.
The primary targets are vertically integrated health conglomerates that own both a PBM and a large pharmacy network. CVS Health (Caremark PBM + CVS Pharmacy) is the most exposed, followed by UnitedHealth Group (Optum Rx PBM + Optum Pharmacy). Cigna (Express Scripts PBM + Evernorth specialty pharmacy) has moderate exposure. Independent pharmacies and chains without PBM ownership (e.g., Walgreens, Rite Aid) would face less direct impact and could benefit from reduced steering to affiliated pharmacies.
Market reaction has been muted given the early stage, but the bill adds legislative overhang. For retail investors, the key risk is a forced divestiture scenario: CVS and UNH would likely be required to spin off either their PBM or pharmacy assets, eliminating cross-selling synergies and potentially unlocking value in separate entities but creating near-term operational disruption. The legislative path requires committee markup, Senate floor vote, House passage, and presidential action—unlikely before the 2026 midterm elections. However, growing bipartisan scrutiny of PBMs (cosponsors include both Democrats and Republicans) suggests this issue has staying power.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition on common ownership of PBM and pharmacy operations
Who must act
CVS Health (owns Caremark PBM and CVS Pharmacy retail chain)
What happens
Forced divestiture of either PBM or pharmacy assets, eliminating vertical integration synergies and market power
Stock impact
CVS derives ~70% of revenue from PBM (Caremark) and retail pharmacy; separation would dismantle cross-subsidization and potentially reduce profitability in both segments
What the bill does
Prohibition on common ownership of PBM and pharmacy operations
Who must act
UnitedHealth Group (owns Optum Rx PBM and Optum Pharmacy, including mail-order and specialty pharmacies)
What happens
Forced divestiture of Optum Rx or Optum Pharmacy, severing vertically integrated pharmacy benefit and pharmacy services
Stock impact
Optum contributes ~40% of UNH's revenue; the PBM and pharmacy operations are key to Optum's value proposition; divestiture would reduce competitive advantage in managing drug costs
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Improving Seniors’ Timely Access to Care Act of 2025
PBM Act
Great American Healthcare Plan
Fair Care Act of 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
To amend title XVIII of the Social Security Act to require certain reporting with respect to agents and brokers of Medicare Advantage organizations.
January 6th Law Enforcement Heroes Compensation Fund Act
A bill to amend title 10, United States Code, to improve access to certain medications under the TRICARE program, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →